The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of stenosis and edema are listed in the xience sierra everolimus eluting coronary stent systems instructions for use (ifu) as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
Patient id: (b)(6).It was reported that the procedure was performed on 10/02/2020 to treat a lesion in the proximal left anterior descending (lad) artery.A 2.75 x 15 mm xience sierra stent and a 2.5 x 28 mm xience sierra stent were implanted.On 04/04/2022, the patient was re-hospitalized with shortness of breath and lower extremity edema.Coronary catheterization was performed and noted 80% in-stent restenosis in the proximal and mid lad, in the 2.5 x 28 mm xience sierra stent and a previously implanted unspecified stent, and 90% stenosis in the circumflex (cx) artery.Angioplasty was performed to treat the in-stent restenosis in the 2.5 x 28 mm xience sierra stent.The event resolved on (b)(6) 2022.A staged procedure will be performed at a later date to treat the cx artery.No additional information was provided.
|